Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
MALVERN, Pa., Feb. 23, 2017 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biotechnology company, will release its fourth quarter financial results before the market opens on March 15, 2017
Management will conduct a conference call at 8:00 a.m. ET that day to discuss the Company’s financial results and provide a general business update. The conference will be webcast live over the Internet and can be accessed by logging on to the “Investors” section of the Aclaris Therapeutics website, www.aclaristx.com, prior to the event. A replay of the webcast will be archived on the Company’s website for 30 days following the call.
To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 62366728 prior to the start of the call.
About Aclaris
Aclaris Therapeutics, Inc. is a clinical-stage dermatologist-led biotechnology company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Contact: Aclaris Contact Michael Tung, M.D. Investor Relations 484-329-2140 [email protected] Media Contact Mariann Caprino TogoRun 917-242-1087 [email protected]
